Compare Blackstone Inc (BX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs Johnson & Johnson — how do they compare? Blackstone Inc trades at $126.43 (market cap $152.15B), while Johnson & Johnson trades at $248 (market cap $611.07B). The key difference: Johnson & Johnson is far larger — about 4× Blackstone Inc's market cap, and Blackstone Inc pays the higher dividend (3.99%). Which is the better fit depends on your goals.
| BX | JNJ | |
|---|---|---|
Market Cap | $152.15B | $611.07B |
Sector | Financials | Health |
52-Week High | $188.68 | $267.24 |
52-Week Low | $102.12 | $155.17 |
Dividend Yield | 3.99% | 2.11% |
Volume | — | 6,156,228 |
Enterprise Value | — | $644.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
